Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

The Tritiated Water Skin Barrier Integrity Test: Considerations for Acceptance Criteria with and Without 14C-Octanol.

Lehman PA, Beatch K, Raney SG, Franz TJ.

Pharm Res. 2017 Jan;34(1):217-228. doi: 10.1007/s11095-016-2057-3. Epub 2016 Nov 7.

PMID:
27822852
2.

Pharmacokinetics-Based Approaches for Bioequivalence Evaluation of Topical Dermatological Drug Products.

Raney SG, Franz TJ, Lehman PA, Lionberger R, Chen ML.

Clin Pharmacokinet. 2015 Nov;54(11):1095-106. doi: 10.1007/s40262-015-0292-0. Review.

PMID:
26063051
3.

Assessing topical bioavailability and bioequivalence: a comparison of the in vitro permeation test and the vasoconstrictor assay.

Lehman PA, Franz TJ.

Pharm Res. 2014 Dec;31(12):3529-37. doi: 10.1007/s11095-014-1439-7. Epub 2014 Jul 9.

PMID:
25005736
4.

Effect of induced acute diabetes and insulin therapy on stratum corneum barrier function in rat skin.

Lehman PA, Franz TJ.

Skin Pharmacol Physiol. 2014;27(5):249-53. doi: 10.1159/000357478. Epub 2014 May 20.

PMID:
24854835
5.

On topical timolol gel-forming solution for infantile hemangiomas.

Berk DR, Lehman PA, Franz TJ, Blunt JR, Bayliss SJ.

Pediatr Dermatol. 2013 Jan-Feb;30(1):160-1. doi: 10.1111/pde.12060. No abstract available.

PMID:
23316722
6.

Assessing the bioequivalence of topical retinoid products by pharmacodynamic assay.

Lehman PA, Franz TJ.

Skin Pharmacol Physiol. 2012;25(5):269-80. doi: 10.1159/000339899. Epub 2012 Jul 27.

PMID:
22847319
7.

Percutaneous absorption in man: in vitro-in vivo correlation.

Lehman PA, Raney SG, Franz TJ.

Skin Pharmacol Physiol. 2011;24(4):224-30. doi: 10.1159/000324884. Epub 2011 Mar 31.

8.

Use of excised human skin to assess the bioequivalence of topical products.

Franz TJ, Lehman PA, Raney SG.

Skin Pharmacol Physiol. 2009;22(5):276-86. doi: 10.1159/000235828. Epub 2009 Aug 26.

9.

Novel lymphocyte-independent mechanisms to initiate inflammatory arthritis via bone marrow-derived cells of Ali18 mutant mice.

Abe K, Wechs S, Kalaydjiev S, Franz TJ, Busch DH, Fuchs H, Soewarto D, Behrendt H, Wagner S, Jakob T, Hrabé de Angelis M.

Rheumatology (Oxford). 2008 Mar;47(3):292-300. doi: 10.1093/rheumatology/kem358.

PMID:
18276736
10.

Generation and characterization of dickkopf3 mutant mice.

Barrantes Idel B, Montero-Pedrazuela A, Guadaño-Ferraz A, Obregon MJ, Martinez de Mena R, Gailus-Durner V, Fuchs H, Franz TJ, Kalaydjiev S, Klempt M, Hölter S, Rathkolb B, Reinhard C, Morreale de Escobar G, Bernal J, Busch DH, Wurst W, Wolf E, Schulz H, Shtrom S, Greiner E, Hrabé de Angelis M, Westphal H, Niehrs C.

Mol Cell Biol. 2006 Mar;26(6):2317-26.

11.

Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.

Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B.

J Am Soc Nephrol. 2005 Dec;16(12):3592-601. Epub 2005 Nov 2.

12.

Sex-dependent susceptibility to Listeria monocytogenes infection is mediated by differential interleukin-10 production.

Pasche B, Kalaydjiev S, Franz TJ, Kremmer E, Gailus-Durner V, Fuchs H, Hrabé de Angelis M, Lengeling A, Busch DH.

Infect Immun. 2005 Sep;73(9):5952-60.

13.

NKG2D-independent suppression of T cell proliferation by H60 and MICA.

Kriegeskorte AK, Gebhardt FE, Porcellini S, Schiemann M, Stemberger C, Franz TJ, Huster KM, Carayannopoulos LN, Yokoyama WM, Colonna M, Siccardi AG, Bauer S, Busch DH.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11805-10. Epub 2005 Aug 9.

14.

Introducing the German Mouse Clinic: open access platform for standardized phenotyping.

Gailus-Durner V, Fuchs H, Becker L, Bolle I, Brielmeier M, Calzada-Wack J, Elvert R, Ehrhardt N, Dalke C, Franz TJ, Grundner-Culemann E, Hammelbacher S, Hölter SM, Hölzlwimmer G, Horsch M, Javaheri A, Kalaydjiev SV, Klempt M, Kling E, Kunder S, Lengger C, Lisse T, Mijalski T, Naton B, Pedersen V, Prehn C, Przemeck G, Racz I, Reinhard C, Reitmeir P, Schneider I, Schrewe A, Steinkamp R, Zybill C, Adamski J, Beckers J, Behrendt H, Favor J, Graw J, Heldmaier G, Höfler H, Ivandic B, Katus H, Kirchhof P, Klingenspor M, Klopstock T, Lengeling A, Müller W, Ohl F, Ollert M, Quintanilla-Martinez L, Schmidt J, Schulz H, Wolf E, Wurst W, Zimmer A, Busch DH, de Angelis MH.

Nat Methods. 2005 Jun;2(6):403-4. No abstract available.

PMID:
15908916
15.

Bioavailability of clobetasol propionate in different vehicles.

Franz TJ, Lehman PA, Feldman SR, Spellman MC.

Skin Pharmacol Appl Skin Physiol. 2003 Jul-Aug;16(4):212-6.

PMID:
12784060
16.

Methods to assess skin penetration.

Franz TJ.

J Cosmet Sci. 2002 Sep-Oct;53(5):292. No abstract available.

PMID:
12384715
17.

Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer.

Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, Bernhard H, Wagner H, Busch DH.

Nat Med. 2002 Jun;8(6):631-7.

PMID:
12042816
18.

Evaluation of creams and ointments as suitable formulations for peldesine.

Viegas TX, Van Winkle LL, Lehman PA, Franz SF, Franz TJ.

Int J Pharm. 2001 May 21;219(1-2):73-80.

PMID:
11337167
19.

Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery.

Franz TJ, Parsell DA, Myers JA, Hannigan JF.

Int J Dermatol. 2000 Jul;39(7):535-8. No abstract available.

PMID:
10940121
20.

Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers.

Everett DW, Franz TJ, Chando TJ, Gale PJ, Lehman PA, Schwarzel EH, Parab PV, D'Arienzo CJ, Kripalani KJ.

Biopharm Drug Dispos. 1999 Sep;20(6):301-8.

PMID:
10701701
21.

Assessment of value and applications of in vitro testing of topical dermatological drug products.

Flynn GL, Shah VP, Tenjarla SN, Corbo M, DeMagistris D, Feldman TG, Franz TJ, Miran DR, Pearce DM, Sequeira JA, Swarbrick J, Wang JC, Yacobi A, Zatz JL.

Pharm Res. 1999 Sep;16(9):1325-30. Review.

22.

Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy.

Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS.

Int J Dermatol. 1999 Aug;38(8):628-32.

PMID:
10487457
23.

Bioequivalence of topical dermatological dosage forms--methods of evaluation of bioequivalence. AAPS/FDA Workshop on 'Bioequivalence of Topical Dermatological Dosage Forms-- Methods of Evaluating Bioequivalence', September 4-6, 1996, Bethesda, Md.

Shah VP, Flynn GL, Yacobi A, Maibach HI, Bon C, Fleischer NM, Franz TJ, Kaplan SA, Kawamoto J, Lesko LJ, Marty JP, Pershing LK, Schaefer H, Sequeira JA, Shrivastava SP, Wilkin J, Williams RL.

Skin Pharmacol Appl Skin Physiol. 1998 Mar-Apr;11(2):117-24. Review. No abstract available.

PMID:
9603663
24.

Bioequivalence of topical dermatological dosage forms--methods of evaluation of bioequivalence.

Shah VP, Flynn GL, Yacobi A, Maibach HI, Bon C, Fleischer NM, Franz TJ, Kaplan SA, Kawamoto J, Lesko LJ, Marty JP, Pershing LK, Schaefer H, Sequeira JA, Shrivastava SP, Wilkin J, Williams RL.

Pharm Res. 1998 Feb;15(2):167-71. No abstract available.

25.
26.

Comparative percutaneous absorption of lindane and permethrin.

Franz TJ, Lehman PA, Franz SF, Guin JD.

Arch Dermatol. 1996 Aug;132(8):901-5.

PMID:
8712839
28.

Free radical oxidation of (E)-retinoic acid by prostaglandin H synthase.

Samokyszyn VM, Chen T, Maddipati KR, Franz TJ, Lehman PA, Lloyd RV.

Chem Res Toxicol. 1995 Jul-Aug;8(5):807-15.

PMID:
7548765
29.

Penetration of glutaraldehyde through glove material: Tactylon versus natural rubber latex.

Lehman PA, Franz TJ, Guin JD.

Contact Dermatitis. 1994 Mar;30(3):176-7. No abstract available.

PMID:
8187522
30.

Topical lidocaine for anesthesia in patients undergoing pulsed dye laser treatment for vascular malformations.

Mallory SB, Lehman PA, Vanderpool DR, Franz TJ.

Pediatr Dermatol. 1993 Dec;10(4):370-5.

PMID:
8302744
31.

Percutaneous penetration of N-nitrosodiethanolamine through human skin (in vitro): comparison of finite and infinite dose applications from cosmetic vehicles.

Franz TJ, Lehman PA, Franz SF, North-Root H, Demetrulias JL, Kelling CK, Moloney SJ, Gettings SD.

Fundam Appl Toxicol. 1993 Aug;21(2):213-21.

PMID:
8405784
32.

Quantitative vasoconstrictor assay for topical corticosteroids: the puzzling case of fluocinolone acetonide.

Guin JD, Wallis MS, Walls R, Lehman PA, Franz TJ.

J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):197-202.

PMID:
8335738
33.
34.

Percutaneous absorption and metabolism of lonapalene in psoriatic skin.

Lehman PA, Tomlinson RV, Johnson JI, Olerud JE, Akers WA, Franz TJ.

Pharm Res. 1992 Sep;9(9):1145-51.

PMID:
1409395
35.

Absorption of amorolfine through human nail.

Franz TJ.

Dermatology. 1992;184 Suppl 1:18-20.

PMID:
1550966
36.
37.

Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days.

McCrea JB, Vlasses PH, Franz TJ, Zeoli L.

Pharmacotherapy. 1990;10(4):289-93.

PMID:
2388875
38.

The hamster flank organ model: is it relevant to man?

Franz TJ, Lehman PA, Pochi P, Odland GF, Olerud J.

J Invest Dermatol. 1989 Oct;93(4):475-9.

39.

Percutaneous absorption of retinoids: influence of vehicle, light exposure, and dose.

Lehman PA, Slattery JT, Franz TJ.

J Invest Dermatol. 1988 Jul;91(1):56-61.

40.

Percutaneous absorption of sulconazole nitrate in humans.

Franz TJ, Lehman P.

J Pharm Sci. 1988 Jun;77(6):489-91.

PMID:
3171926
41.

Vehicle effects on percutaneous absorption: in vivo and in vitro comparisons with human skin.

Bronaugh RL, Franz TJ.

Br J Dermatol. 1986 Jul;115(1):1-11.

PMID:
3730275
42.

Minimal spinal hyperostosis with low-dose isotretinoin therapy.

Kilcoyne RF, Cope R, Cunningham W, Nardella FA, Denman S, Franz TJ, Hanifin J.

Invest Radiol. 1986 Jan;21(1):41-4.

PMID:
2935510
43.

Topically applied minoxidil in baldness.

Novak E, Franz TJ, Headington JT, Wester RC.

Int J Dermatol. 1985 Mar;24(2):82-7. Review. No abstract available.

44.

Percutaneous absorption of minoxidil in man.

Franz TJ.

Arch Dermatol. 1985 Feb;121(2):203-6.

PMID:
3977334
45.

Pharmacokinetics of the poly-gamma-glutamyl metabolites of methotrexate in skin and other tissues of rats and hairless mice.

Zimmerman CL, Franz TJ, Slattery JT.

J Pharmacol Exp Ther. 1984 Nov;231(2):242-7.

PMID:
6208357
46.

Persistence of antifolate activity in skin of rats following systemic administration of methotrexate.

Zimmerman CL, Franz TJ, Slattery JT.

J Invest Dermatol. 1984 Jan;82(1):57-61.

47.

Kinetics of cutaneous drug penetration.

Franz TJ.

Int J Dermatol. 1983 Nov;22(9):499-505. Review. No abstract available.

PMID:
6358066
48.

On the bioavailability of topical formulations of clindamycin hydrochloride.

Franz TJ.

J Am Acad Dermatol. 1983 Jul;9(1):66-73.

PMID:
6886106
49.

An unusual cause of an indolent skin infection.

Zumwalt RD, Franz TJ.

Arch Dermatol. 1983 Jul;119(7):624-5. No abstract available.

PMID:
6344802
50.

Supplemental Content

Loading ...
Support Center